Skip to main content
SpringerLink
Log in

Investigational Therapies for Prostate Cancer

  • Chapter
Book cover Urological Oncology

  • 761 Accesses

Abstract

Universal agreement has not been reached as to the best treatment for cancer of the prostate (CaP) at any stage. Radical prostatectomy, external-beam radiation therapy, and brachytherapy are potentially curative in patients with clinically localized disease. Despite the widespread use of prostate-specific antigen (PSA) in early detection and screening, significant numbers of cases are not diagnosed until the disease has advanced or metastasized beyond the reach of these local treatment modalities. Hormonal therapy and chemotherapy are the only other systemic treatments available at the present time. Because of the limitations of current local and systemic therapies for prostate cancer, there is a continued interest in the development of new treatment modalities. This chapter discusses some of the therapies and their principles that are being investigated in CaP.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Sikora K, Pandha H. Gene therapy for prostate cancer. Br J Urol 1997;79(suppl 2): 64–68.

    PubMed  Google Scholar 

  2. Anderson WF, Blaese RM, Culver K. The ADA human gene therapy clinical protocol: points to consider response with clinical protocol, July 6, 1990. Hum Gene Ther 1990;1(3):331–362.

    Article  PubMed  Google Scholar 

  3. Simons JW, Mikhak B, Chang JF, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999;59(20):5160–5168.

    CAS  PubMed  Google Scholar 

  4. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventionaldose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediateto high-risk prostate cancer. Cancer Res 2003;63(21): 7497–7506.

    CAS  PubMed  Google Scholar 

  5. Downing SR, Russell PJ, Jackson P. Alterations of p53 are common in early stage prostate cancer. Can J Urol 2003;10(4):1924–1933.

    PubMed  Google Scholar 

  6. Pisters LL, Pettaway CA, Troncoso P, et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 2004; 10(8):2587–2593.

    Article  CAS  PubMed  Google Scholar 

  7. Mikata K, Uemura H, Ohuchi H, et al. Inhibition of growth of human prostate cancer xenograft by transfection of p53 gene: gene transfer by electroporation. Mol Cancer Ther 2002;1(4):247–252.

    CAS  PubMed  Google Scholar 

  8. Tanaka M, Rosser CJ, Grossman HB. PTEN gene therapy induces growth inhibition and increases efficacy of chemotherapy in prostate cancer. Cancer Det Prev 2005; 29(2):170–174.

    Article  CAS  Google Scholar 

  9. Rosser CJ, Tanaka M, Pisters LL, et al. Adenoviral-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther 2004;11(4):273–279.

    Article  CAS  PubMed  Google Scholar 

  10. Iversen PL, Arora V, Acker AJ, Mason DH, Devi GR. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 2003;9(7):2510–2519.

    CAS  PubMed  Google Scholar 

  11. Shi XB, Gumerlock PH, Muenzer JT, deVere White RW. BCL2 antisense transcripts decrease intracellular Bcl2 expression and sensitize LNCaP prostate cancer cells to apoptosis-inducing agents. Cancer Biother Radiopharm 2001;16(5):421–429.

    Article  CAS  PubMed  Google Scholar 

  12. Cao G, Su J, Lu W, et al. Adenovirus-mediated interferon-beta gene therapy suppresses growth and metastasis of human prostate cancer in nude mice. Cancer Gene Ther 2001;8(7):497–505.

    Article  CAS  PubMed  Google Scholar 

  13. Cheng WS, Kraaij R, Nilsson B, et al. A novel TARP-promoter-based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol Ther 2004;10(2):355–364.

    Article  CAS  PubMed  Google Scholar 

  14. Li X, Raikwar SP, Liu YH, et al. Combination therapy of androgen-independent prostate cancer using a prostate restricted replicative adenovirus and a replication-defective adenovirus encoding human endostatin-angiostatin fusion gene. Mol Cancer Ther 2006;5(3):676–684.

    Article  CAS  PubMed  Google Scholar 

  15. Gene Therapy Clinical Trials Worldwide. New York: Wiley Interscience, 2006. http://www.wiley.co.uk/genetherapy/clinical/.

    Google Scholar 

  16. Kaminski JM, Summers JB, Ward MB, Huber MR, Minev B. Immunotherapy and prostate cancer. Cancer Treat Rev 2003;29(3):199–209.

    Article  CAS  PubMed  Google Scholar 

  17. Simons JW, Carducci MA, Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res 2006; 12(11pt 1):3394–3401.

    Article  CAS  PubMed  Google Scholar 

  18. Michael A, Ball G, Quatan N, et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005;11(12):4469–4478.

    Article  CAS  PubMed  Google Scholar 

  19. Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000;18(23):3894–3903.

    CAS  PubMed  Google Scholar 

  20. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21(4): 679–689.

    Article  CAS  PubMed  Google Scholar 

  21. Zeng G, Wang X, Robbins PF, Rosenberg SA, Wang RF. CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Nat Acad Sci USA 2001; 98(7):3964–3969.

    Article  CAS  PubMed  Google Scholar 

  22. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005;4(1):55–60.

    CAS  PubMed  Google Scholar 

  23. Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24(19): 3089–3094.

    Article  CAS  PubMed  Google Scholar 

  24. Rochlitz C, Figlin R, Squiban P, et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J Gene Med 2003;5(8):690–699.

    Article  CAS  PubMed  Google Scholar 

  25. Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897):a trial of the Eastern Cooperative Oncology Group. J Clin Oncol 2004;22(11):2122–2132.

    Article  CAS  PubMed  Google Scholar 

  26. Madersbacher S, Kratzik C, Szabo N, et al. Tissue ablation in benign prostatic hyperplasia with high-intensity focused ultrasound. Eur Urol 1993;23(suppl 1):39–43.

    PubMed  Google Scholar 

  27. Gelet A, Chapelon JY, Bouvier R, et al. Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996;29(2):174–183.

    CAS  PubMed  Google Scholar 

  28. Rebillard X, Gelet A, Davin JL, et al. Transrectal high-intensity focused ultrasound in the treatment of localized prostate cancer. J Endourol 2005;19(6):693–701.

    Article  PubMed  Google Scholar 

  29. Gelet A, Chapelon JY, Poissonnier L, et al. Local recurrence of prostate cancer after external beam radiotherapy: early experience of salvage therapy using high-intensity focused ultrasonography. Urology 2004;63(4):625–629.

    Article  PubMed  Google Scholar 

  30. Wang ZB, Wu F, Wang ZL, et al. Targeted damage effects of high intensity focused ultrasound (HIFU) on liver tissues of Guizhou Province miniswine. Ultrason Sonochem 1997;4(2):181–182.

    Article  CAS  PubMed  Google Scholar 

  31. Yang R, Sanghvi NT, Rescorla FJ, et al. Extracorporeal liver ablation using sonography-guided high-intensity focused ultrasound. Invest Radiol 1992;27(10):796–803.

    Article  CAS  PubMed  Google Scholar 

  32. Vaezy S, Shi X, Martin RW, et al. Real-time visualization of high-intensity focused ultrasound treatment using ultrasound imaging. Ultrasound Med Biol 2001;27(1): 33–42.

    Article  CAS  PubMed  Google Scholar 

  33. Azzouz H, de la Rosette JJMCH. HIFU: local treatment of prostate cancer. Eur Urol 2006;4(EAU series):62–70.

    Google Scholar 

  34. Hummel S, Paisley S, Morgan A, Currie E, Brewer N. Clinical and cost-effectiveness of new and emerging technologies for early localised prostate cancer: a systematic review. Health Technol Assess 2003;7(33):iii, ix–x, 1–157.

    CAS  PubMed  Google Scholar 

  35. Beerlage HP, Thuroff S, Debruyne FM, Chaussy C, de la Rosette JJ. Transrectal high-intensity focused ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology 1999;54(2):273–277.

    Article  CAS  PubMed  Google Scholar 

  36. Chaussy C, Thuroff S. High-intensity focused ultrasound in prostate cancer: results after 3 years. Mol Urol 2000;4(3):179–182.

    CAS  PubMed  Google Scholar 

  37. Madersbacher S, Pedevilla M, Vingers L, Susani M, Marberger M. Effect of high-intensity focused ultrasound on human prostate cancer in vivo. Cancer Res 1995; 55(15):3346–3351.

    CAS  PubMed  Google Scholar 

  38. Gelet A, Chapelon JY, Bouvier R, et al. Transrectal high intensity focused ultrasound for the treatment of localized prostate cancer: factors influencing the outcome. Eur Urol 2001;40:124–129.

    Article  CAS  PubMed  Google Scholar 

  39. Chaussy C, Thuroff S. The status of high-intensity focused ultrasound in the treatment of localized prostate cancer and the impact of a combined resection. Curr Urol Rep 2003;4:248–252.

    Article  PubMed  Google Scholar 

  40. Uchida T, Ohkusa H, Nagata Y, et al. Treatment of localized prostate cancer using high-intensity focused ultrasound. BJU Int 2006;97(1):56–61.

    Article  PubMed  Google Scholar 

  41. Thuroff S, Chaussy C, Vallancien G, et al. High-intensity focused ultrasound and localized prostate cancer: efficacy results from the European multicentric study. J Endourol 2003;17(8):673–677.

    Article  PubMed  Google Scholar 

  42. Blana A, Walter B, Rogenhofer S, Wieland WF. High-intensity focused ultrasound for the treatment of localized prostate cancer: 5-year experience. Urology 2004;63(2): 297–300.

    Article  PubMed  Google Scholar 

  43. Kiel HJ, Wieland WF, Rossler W. Local control of prostate cancer by transrectal HIFU-therapy. Arch Ital Urol Androl 2000;72(4):313–319.

    CAS  PubMed  Google Scholar 

  44. Gonder MJ, Soanes WA, Shulman S. Cryosurgical treatment of the prostate. Invest Urol 1966;3(4):372–378.

    CAS  PubMed  Google Scholar 

  45. Flocks RH, Nelson CM, Boatman DL. Perineal cryosurgery for prostatic carcinoma. J Urol 1972;108(6):933–935.

    CAS  PubMed  Google Scholar 

  46. Megalli MR, Gursel EO, Veenema RJ. Closed perineal cryosurgery in prostatic cancer. New probe and technique. Urology 1974;4(2):220–222.

    Article  CAS  PubMed  Google Scholar 

  47. Onik GM, Cohen JK, Reyes GD, et al. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer 1993;72(4):1291–1299.

    Article  CAS  PubMed  Google Scholar 

  48. Onik G, Cobb C, Cohen J, Zabkar J, Porterfield B. US characteristics of frozen prostate. Radiology 1988;168(3):629–631.

    CAS  PubMed  Google Scholar 

  49. Lee F, Bahn DK, McHugh TA, Onik GM, Lee FT Jr. US-guided percutaneous cryoablation of prostate cancer. Radiology 1994;192(3):769–776.

    CAS  PubMed  Google Scholar 

  50. Wong WS, Chinn DO, Chinn M, et al. Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer 1997;79(5):963–974.

    Article  CAS  PubMed  Google Scholar 

  51. Pisters LL, von Eschenbach AC, Scott SM, et al. The efficacy and complications of salvage cryotherapy of the prostate. J Urol 1997;157(3):921–925.

    Article  CAS  PubMed  Google Scholar 

  52. Ahmed S, Lindsey B, Davies J. Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy. Prostate Cancer Prostatic Dis 2005;8(1):31–35.

    Article  CAS  PubMed  Google Scholar 

  53. Shinohara K, Connolly JA, Presti JC Jr, Carroll PR. Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. J Urol 1996;156(1):115–220; discussion 20–21.

    Article  CAS  PubMed  Google Scholar 

  54. Cohen JK, Miller RJ, Rooker GM, Shuman BA. Cryosurgical ablation of the prostate: two-year prostate-specific antigen and biopsy results. Urology 1996;47(3): 395–401.

    Article  CAS  PubMed  Google Scholar 

  55. Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J Urol 1999;162(2):427–432.

    Article  CAS  PubMed  Google Scholar 

  56. Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001;57(3):518–523.

    Article  CAS  PubMed  Google Scholar 

  57. Bahn DK, Lee F, Silverman P, et al. Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer 2003;2(2): 111–114.

    PubMed  Google Scholar 

  58. Beerlage HP, Thuroff S, Madersbacher S, et al. Current status of minimally invasive treatment options for localized prostate carcinoma. Eur Urol 2000;37(1): 2–13.

    Article  CAS  PubMed  Google Scholar 

  59. Bagshaw MA, Prionas SD, Goffinet DR, et al. External beam irradiation combined with the use of 192-iridium implants and radiofrequency-induced hyperthermia in the treatment of prostatic carcinoma. Prog Clin Biol Res 1991;370:275–279.

    CAS  PubMed  Google Scholar 

  60. Zlotta AR, Djavan B, Matos C, et al. Percutaneous transperineal radiofrequency ablation of prostate tumour: safety, feasibility and pathological effects on human prostate cancer. Br J Urol 1998;81(2):265–275.

    CAS  PubMed  Google Scholar 

  61. Shariat SF, Raptidis G, Masatoschi M, Bergamaschi F, Slawin KM. Pilot study of radiofrequency interstitial tumor ablation (RITA) for the treatment of radio-recurrent prostate cancer. Prostate 2005;65(3):260–267.

    Article  CAS  PubMed  Google Scholar 

  62. Johannsen M, Thiesen B, Jordan A, et al. Magnetic fluid hyperthermia (MFH) reduces prostate cancer growth in the orthotopic Dunning R3327 rat model. Prostate 2005; 64(3):283–292.

    Article  PubMed  Google Scholar 

  63. Johannsen M, Jordan A, Scholz R, et al. Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. J Endourol 2004;18(5):495–500.

    Article  PubMed  Google Scholar 

  64. Johannsen M, Thiesen B, Gneveckow U, et al. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer. Prostate 2006;66(1):97–104.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, St. Bartholomew’s Hospital, West Smithfield London, UK

    Suresh Radhakrishnan MBBS, MS, MRCS

  2. Department of Urology, St. Bartholomew’s Hospital, London, UK

    Frank Chinegwundoh MBBS, MS, FRCS(Urol), FEBU

Authors
  1. Suresh Radhakrishnan MBBS, MS, MRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Chinegwundoh MBBS, MS, FRCS(Urol), FEBU
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. St. Bartholomew’s and Homerton Hospitals Queen Mary Barts and the London School of Medicine and Dentistry, University of London, London, UK

    Vinod H. Nargund PhD, FRCS (Urol), FEBU (Chair, Uro-Oncology MDT and Consultant Urological Surgeon) (Chair, Uro-Oncology MDT and Consultant Urological Surgeon)

  2. Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    Derek Raghavan MD, PhD, FACP, FRACP (Chairman and Director) (Chairman and Director)

  3. Department of Radiation Oncology, University of Michigan, Ann Arbor, MI, USA

    Howard M. Sandler MD (Professor and Senior Associate Chair) (Professor and Senior Associate Chair)

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag London Limited

About this chapter

Cite this chapter

Radhakrishnan, S., Chinegwundoh, F. (2008). Investigational Therapies for Prostate Cancer. In: Nargund, V.H., Raghavan, D., Sandler, H.M. (eds) Urological Oncology. Springer, London. https://doi.org/10.1007/978-1-84628-738-1_32

Download citation

  • DOI: https://doi.org/10.1007/978-1-84628-738-1_32

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-84628-387-1

  • Online ISBN: 978-1-84628-738-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation